HC Wainwright Issues Pessimistic Estimate for SRTS Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Stock analysts at HC Wainwright dropped their Q2 2025 earnings per share estimates for shares of Sensus Healthcare in a research note issued on Monday, February 10th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of $0.07 per share for the quarter, down from their previous estimate of $0.10. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.71 per share. HC Wainwright also issued estimates for Sensus Healthcare’s FY2025 earnings at $0.44 EPS.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%.

Other research analysts also recently issued reports about the company. Maxim Group boosted their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Lake Street Capital assumed coverage on Sensus Healthcare in a research note on Friday, January 31st. They issued a “buy” rating and a $18.00 price objective on the stock.

Sensus Healthcare Trading Down 2.7 %

Shares of SRTS opened at $5.50 on Wednesday. The company has a market capitalization of $90.15 million, a PE ratio of 13.75 and a beta of 1.24. The stock’s 50-day moving average price is $7.22 and its two-hundred day moving average price is $6.88. Sensus Healthcare has a 12 month low of $2.91 and a 12 month high of $9.33.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new stake in Sensus Healthcare in the 4th quarter valued at about $27,000. Barclays PLC bought a new stake in Sensus Healthcare in the 4th quarter valued at about $35,000. Truvestments Capital LLC bought a new stake in Sensus Healthcare in the 3rd quarter valued at about $32,000. Geode Capital Management LLC increased its position in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after buying an additional 11,525 shares in the last quarter. Finally, XTX Topco Ltd increased its position in Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after buying an additional 13,619 shares in the last quarter. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.